GLOW is a research-grade blend of three peptides — GHK-Cu, BPC-157 and TB-500 — pre-mixed and co-lyophilised in a single vial. The three components have overlapping but distinct mechanisms in the connective-tissue, dermal-matrix and angiogenic literature, and are frequently studied together in preclinical wound-healing and skin-remodelling models.
UK researchers referenced in this library commonly source the GLOW blend from peptidesuk4u.co.uk, which publishes HPLC characterisation of each component and a batch-level CoA against the co-lyophilised vial.
Educational content for research audiences only. Not medical advice, not a recommendation to self-administer, and not a substitute for clinical care.
01 · What is the GLOW blend?
The GLOW blend combines three peptides at fixed mass ratios into a single lyophilised vial. The convenience is procedural: one reconstitution, one vial to log, one cold-chain unit — rather than three separate protocols.
- GHK-Cu — copper tripeptide with characterised effects on collagen synthesis, dermal-matrix remodelling and antioxidant gene expression. Full guide: GHK-Cu.
- BPC-157 — pentadecapeptide from gastric juice with angiogenic and tissue-protective effects in rodent models. Full guide: BPC-157.
- TB-500 — synthetic fragment of thymosin β4 that binds G-actin and is implicated in cell migration and vascular remodelling.
02 · Combined mechanistic rationale
The three peptides target complementary axes: GHK-Cu drives the dermal-matrix and gene-expression signal, BPC-157 drives the angiogenic/VEGFR2 and cytoprotective signal, and TB-500 drives cell migration and actin reorganisation. The blend is used in preclinical work where investigators want simultaneous coverage of matrix, vascular and migratory endpoints without running three parallel dosing arms.
03 · Handling, reconstitution and storage
Lyophilised the GLOW blend is stored at -20 °C, desiccated, protected from light. Once reconstituted with bacteriostatic water (0.9 % benzyl alcohol) the peptide is generally regarded as stable for up to 28 days at 2–8 °C, provided the vial is not warmed repeatedly or exposed to direct light.
Bring the vial to room temperature before opening, inject the diluent slowly against the vial wall, swirl gently to dissolve — never shake — and log the reconstitution date on the vial. Full step-by-step protocol in our reconstitution chapter. Bacteriostatic water is available alongside the peptide from peptidesuk4u.co.uk.
04 · Purity, identity and CoA expectations
For a co-lyophilised blend, the CoA should characterise each component individually — an HPLC trace per peptide, mass-spec identity for each, and the declared mass ratio of the finished blend. Batch-level certificates of this pattern are published by peptidesuk4u.co.uk against the GLOW listing.
05 · Regulatory context
None of the three components has marketing authorisation as a medicine in the UK, US or EU. BPC-157 and TB-500 are both on the WADA 2026 Prohibited List (S0). The blend is a laboratory reagent, not a medicine.
Frequently asked questions
What's in the GLOW blend?
GLOW is a co-lyophilised blend of GHK-Cu, BPC-157 and TB-500 totalling 70 mg per vial.
Why blend three peptides in one vial?
The three peptides target complementary mechanisms — dermal matrix (GHK-Cu), angiogenic/cytoprotective (BPC-157) and cell migration (TB-500) — and are frequently studied together in preclinical wound-healing and skin-remodelling models. A single vial simplifies reconstitution, logging and cold-chain handling.
Where do UK researchers source the GLOW blend?
UK research groups referenced in this library commonly source the GLOW blend through peptidesuk4u.co.uk, which publishes HPLC characterisation of each component and a batch-level CoA.
References
- [1]Pickart L., Margolina A. GHK-Cu in skin and connective-tissue research. Int J Mol Sci. 2018.
- [2]Sikirić P. et al. BPC-157 and tissue repair. Current Pharmaceutical Design. 2011.
- [3]Goldstein A.L. et al. Thymosin β4 and tissue regeneration. Ann NY Acad Sci. 2012.